 The primary aim of this trial is to determine whether lymphadenectomy, used to restrict adjuvant therapy other than vaginal brachytherapy to node positive women, results in a non-inferior survival as compared to adjuvant therapy given to all women with high risk apparent stage 1 endometrial cancer. 